Bti tn 5b1 4

HEK293 cells were obtained from ATCC (Manassas VA) (CRL-1573), CHO-K1 EA-arrestin cell line from DiscoverX (Fremont CA) and the Flp-In TREx 293 cell line from Invitrogen (Carlsbad CA). Hi5 cells were from Invitrogen (BTI-TN-5B1-4), SF9 cells were from ATCC (CTL-1711), HEK293GnTI- cells were provided by Prof. H.G. Khorana, and EBY100 yeast cells were provided by Prof. Dane Wittrup. Cell line authentication was guaranteed by the sources where the cells were bought. All eukaryotic cell lines used for signaling and functional assays were tested negative for mycoplasma on a regular basis, before and during tissue culture.

HEp-2 cells (ATCC, CCL-23) were maintained in MEM with Earle’s salts, L-glutamine (Gibco Laboratories, Gaithersburg, MD, USA), 5% fetal bovine serum (FBS, Hyclone, Logan UT, USA) and antibiotics (Life Technologies, Grand Island, NY, USA). Spodoptera frugiperda (Sf9) insect cells (Invitrogen, Grand Island, NY, USA) were maintained in serum free medium as suspension cultures. Trichoplusia ni High Five cells (BTI-TN-5B1-4, ATCC CRL-10859) were maintained in Insect-XPRESS Medium with L-glutamine and antibiotics (Lonza, Walkersville, MD, USA). RSV/A Long (ATCC, VR-26) reference strain was obtained from ATCC (Manassas, VA, USA). Virus stock was prepared from clarified supernatants and stored at -80°C in PBS with 25% sucrose as a cryo-protectant. Palivizumab (Synagis) was obtained from MedImmune, Inc. (Gaithersburg, MD, USA) and motavizumab from National Institute of Standards and Technology (Gaithersburg, MD, USA). D25 [17 (link)] (Creative Biolabs, Shirley, NY, USA) and RSHZ19 [45 (link)] (Absolute Antibody, Oxford, UK) were purchased commercially. RSV14N4 and RSV3J20 [30 (link)] were kindly provided by Dr. J. Crowe (Vanderbilt University, Nashville, TN, USA). Palivizumab site II synthetic peptide and its various truncations were commercially synthesized by Peptide 2.0 (Chantilly, VA, USA).